Faecal microbiota transplantation: Key points to consider.
Faecal microbiota transplantation (FMT) from a healthy donor has become the gold standard treatment for patients suffering from recurrent Clostridium difficile infection where antibiotic treatment (with vancomycin, metronidazole or fidaxomicin) has failed. FMT eradicates C. difficile and helps restore the recipient's intestinal flora, but its mechanism of action remains unclear. Since FMT's complex and highly variable composition cannot be easily characterized - nor its quality routinely assessed - FMT as a sui generis biologic drug cannot conform to existing standards for preparation. Clearly, donors must be carefully selected and the raw material prepared under close microbiological control, but FMT should also conform to manufacturing and laboratory practice standards for which international consensus can only be achieved with further experience. The objective should be to engage biomedical research to develop protocols that help elucidate the mechanism of action of FMT and support the production of safe and efficacious products.
Académie de pharmacie, 4, avenue de l'Observatoire, 75270 Paris cedex 06, France; Microbiologie, faculté de pharmacie, université Paris-Sud, rue J.B.-Clément, 92390 Chatenay-Malabry cedex, France. Electronic address: pierre.bourlioux@u-psud.fr.
P
P
Bourlioux
D016360:Clostridioides difficile; D004761:Enterocolitis, Pseudomembranous / Q000628:therapy; D000069467:Fecal Microbiota Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D064307:Microbiota; D012008:Recurrence
Faecal microbiota transplantation; Infection à Clostridium difficile; Recurrent Clostridium difficile infections; Transfert de microbiote fécal